KR20210106504A - 치환된 옥소피리딘 유도체 - Google Patents
치환된 옥소피리딘 유도체 Download PDFInfo
- Publication number
- KR20210106504A KR20210106504A KR1020217022510A KR20217022510A KR20210106504A KR 20210106504 A KR20210106504 A KR 20210106504A KR 1020217022510 A KR1020217022510 A KR 1020217022510A KR 20217022510 A KR20217022510 A KR 20217022510A KR 20210106504 A KR20210106504 A KR 20210106504A
- Authority
- KR
- South Korea
- Prior art keywords
- mmol
- equiv
- methyl
- mixture
- represents hydrogen
- Prior art date
Links
- 0 *C(C(O)=O)N(C=C(C(c1c2*)=C3)OC(*)C(*)Cc1c(*)c(*)c2Cl)C3=O Chemical compound *C(C(O)=O)N(C=C(C(c1c2*)=C3)OC(*)C(*)Cc1c(*)c(*)c2Cl)C3=O 0.000 description 4
- KZDDFXPMYAEDRB-UHFFFAOYSA-N CC(C)(C)OC(C(CC1OCCCC1)Br)=O Chemical compound CC(C)(C)OC(C(CC1OCCCC1)Br)=O KZDDFXPMYAEDRB-UHFFFAOYSA-N 0.000 description 1
- MWUKVLZADCLERI-CYBMUJFWSA-N CC(C)(C)OC(CN(C=C(C(c1c(C2)ccc(Cl)c1)=C1)OC[C@@H]2C(F)(F)F)C1=O)=O Chemical compound CC(C)(C)OC(CN(C=C(C(c1c(C2)ccc(Cl)c1)=C1)OC[C@@H]2C(F)(F)F)C1=O)=O MWUKVLZADCLERI-CYBMUJFWSA-N 0.000 description 1
- IEWAQBGMPXBNGF-UHFFFAOYSA-N CC(C)(C)OC(Nc(c(Br)c1F)ccc1Cl)=O Chemical compound CC(C)(C)OC(Nc(c(Br)c1F)ccc1Cl)=O IEWAQBGMPXBNGF-UHFFFAOYSA-N 0.000 description 1
- ICQMGVWGYITRTC-UHFFFAOYSA-N CC(C)(C)OC(Nc1cc2nnc(C)[n]2cc1)=O Chemical compound CC(C)(C)OC(Nc1cc2nnc(C)[n]2cc1)=O ICQMGVWGYITRTC-UHFFFAOYSA-N 0.000 description 1
- REDFFCFQCFRZIP-OQHSHRKDSA-N CC(C)OCCC(C(OC(C)(C)C)=O)N(C=C(C(c1c(C2)ccc(Cl)c1)=C1)OC[C@@H]2C(F)(F)F)C1=O Chemical compound CC(C)OCCC(C(OC(C)(C)C)=O)N(C=C(C(c1c(C2)ccc(Cl)c1)=C1)OC[C@@H]2C(F)(F)F)C1=O REDFFCFQCFRZIP-OQHSHRKDSA-N 0.000 description 1
- VIYNNJMVVDCMCO-UHFFFAOYSA-N CC(C1)C(C)Oc(cnc(OC)c2)c2-c2c1ccc(Cl)c2 Chemical compound CC(C1)C(C)Oc(cnc(OC)c2)c2-c2c1ccc(Cl)c2 VIYNNJMVVDCMCO-UHFFFAOYSA-N 0.000 description 1
- HMZDGAJEUXOXGS-UHFFFAOYSA-N CC(Cc(c(-c(cc(nc1)OC)c1O)c1)ccc1Cl)CO Chemical compound CC(Cc(c(-c(cc(nc1)OC)c1O)c1)ccc1Cl)CO HMZDGAJEUXOXGS-UHFFFAOYSA-N 0.000 description 1
- UCQJLZZPGFDCFX-UHFFFAOYSA-N CC1(CC1)OCCOS(C(F)(F)F)(=O)=O Chemical compound CC1(CC1)OCCOS(C(F)(F)F)(=O)=O UCQJLZZPGFDCFX-UHFFFAOYSA-N 0.000 description 1
- QYIZHCJCTNBQPL-DVECYGJZSA-N CC1(CC1)OCC[C@@H](C(Nc(cc1)ccc1C(N)=O)=O)N(C=C(C(c1cc(Cl)ccc1C1)=C2)OC[C@@H]1C(F)(F)F)C2=O Chemical compound CC1(CC1)OCC[C@@H](C(Nc(cc1)ccc1C(N)=O)=O)N(C=C(C(c1cc(Cl)ccc1C1)=C2)OC[C@@H]1C(F)(F)F)C2=O QYIZHCJCTNBQPL-DVECYGJZSA-N 0.000 description 1
- NMKLMDTUKFXIJK-UHFFFAOYSA-N CCOC(CCC(C(F)(F)F)O[Si](C)(C)C(C)(C)C)=O Chemical compound CCOC(CCC(C(F)(F)F)O[Si](C)(C)C(C)(C)C)=O NMKLMDTUKFXIJK-UHFFFAOYSA-N 0.000 description 1
- DAXYXZZTMIGECZ-UHFFFAOYSA-N CNCOC(CCC1CCC1)=O Chemical compound CNCOC(CCC1CCC1)=O DAXYXZZTMIGECZ-UHFFFAOYSA-N 0.000 description 1
- QYSQTRLPPNHDAZ-FAEBNJMLSA-N C[C@@H](CC(C(Nc1cc2n[n](C)nc2cc1)=O)N(C(C=C1c2cc(Cl)ccc2C2)O)C=C1OC[C@@H]2C(F)(F)F)OC Chemical compound C[C@@H](CC(C(Nc1cc2n[n](C)nc2cc1)=O)N(C(C=C1c2cc(Cl)ccc2C2)O)C=C1OC[C@@H]2C(F)(F)F)OC QYSQTRLPPNHDAZ-FAEBNJMLSA-N 0.000 description 1
- MAIZWYPQSMMHOQ-OXTHUFEASA-N C[C@@H](C[C@@H](C(Nc(cc1)ccc1C(N)=O)=O)N(C=C(C(c(c(C1)ccc2Cl)c2Cl)=C2)OC[C@@H]1C(F)(F)F)C2=O)OC Chemical compound C[C@@H](C[C@@H](C(Nc(cc1)ccc1C(N)=O)=O)N(C=C(C(c(c(C1)ccc2Cl)c2Cl)=C2)OC[C@@H]1C(F)(F)F)C2=O)OC MAIZWYPQSMMHOQ-OXTHUFEASA-N 0.000 description 1
- ULLZJTVTUUUKPL-OXTHUFEASA-N C[C@@H](C[C@@H](C(Nc(cc1)ccc1C(N)=O)=O)N(C=C(C(c(c(C1)ccc2Cl)c2F)=C2)OC[C@@H]1C(F)(F)F)C2=O)OC Chemical compound C[C@@H](C[C@@H](C(Nc(cc1)ccc1C(N)=O)=O)N(C=C(C(c(c(C1)ccc2Cl)c2F)=C2)OC[C@@H]1C(F)(F)F)C2=O)OC ULLZJTVTUUUKPL-OXTHUFEASA-N 0.000 description 1
- DTYHJANRSKVFEJ-ICKUNSISSA-N C[C@@H](C[C@@H](C(Nc1cc2n[n](C)nc2cc1)=O)N(C=C(C(c1cc(Cl)ccc1C1)=C2)OC[C@@H]1C(F)(F)F)C2=O)OC Chemical compound C[C@@H](C[C@@H](C(Nc1cc2n[n](C)nc2cc1)=O)N(C=C(C(c1cc(Cl)ccc1C1)=C2)OC[C@@H]1C(F)(F)F)C2=O)OC DTYHJANRSKVFEJ-ICKUNSISSA-N 0.000 description 1
- SPGSRNKFQWMVFL-JIGPKXGUSA-N C[C@@H](C[C@@H](C(Nc1cc2ncn[n]2cc1)=O)N(C=C(C(c1c(C2)ccc(Cl)c1)=C1)OC[C@@H]2C(F)(F)F)C1=O)OC Chemical compound C[C@@H](C[C@@H](C(Nc1cc2ncn[n]2cc1)=O)N(C=C(C(c1c(C2)ccc(Cl)c1)=C1)OC[C@@H]2C(F)(F)F)C1=O)OC SPGSRNKFQWMVFL-JIGPKXGUSA-N 0.000 description 1
- SFSGVAXYLZLWLG-RXMQYKEDSA-N C[C@H](C(Nc1ccc(C(N)=O)c(F)c1)=O)Br Chemical compound C[C@H](C(Nc1ccc(C(N)=O)c(F)c1)=O)Br SFSGVAXYLZLWLG-RXMQYKEDSA-N 0.000 description 1
- LZHWYHMQAHJCFX-SRVWHDFXSA-N C[C@H](C[C@@H](C(Nc(cc1)ccc1C(N)=O)=O)N(C=C(C(c1cc(Cl)ccc1C1)=C2)OC[C@@H]1C(F)(F)F)C2=O)OC(F)F Chemical compound C[C@H](C[C@@H](C(Nc(cc1)ccc1C(N)=O)=O)N(C=C(C(c1cc(Cl)ccc1C1)=C2)OC[C@@H]1C(F)(F)F)C2=O)OC(F)F LZHWYHMQAHJCFX-SRVWHDFXSA-N 0.000 description 1
- UUYMQLHUZCLECS-SECBINFHSA-N C[C@H](Cc(c(C1=C2)c3)ccc3Cl)COC1=CNC2=O Chemical compound C[C@H](Cc(c(C1=C2)c3)ccc3Cl)COC1=CNC2=O UUYMQLHUZCLECS-SECBINFHSA-N 0.000 description 1
- MCOPHZCJGZMURT-CKAQCJTGSA-N NC(c(c(F)c1)ccc1NC(C(CCOC(F)F)N(C=C(C(c1cc(Cl)ccc1C1)=C2)OC[C@@H]1C(F)(F)F)C2=O)=O)=O Chemical compound NC(c(c(F)c1)ccc1NC(C(CCOC(F)F)N(C=C(C(c1cc(Cl)ccc1C1)=C2)OC[C@@H]1C(F)(F)F)C2=O)=O)=O MCOPHZCJGZMURT-CKAQCJTGSA-N 0.000 description 1
- MCOPHZCJGZMURT-SZNDQCEHSA-N NC(c(c(F)c1)ccc1NC([C@H](CCOC(F)F)N(C=C(C(c1cc(Cl)ccc1C1)=C2)OC[C@@H]1C(F)(F)F)C2=O)=O)=O Chemical compound NC(c(c(F)c1)ccc1NC([C@H](CCOC(F)F)N(C=C(C(c1cc(Cl)ccc1C1)=C2)OC[C@@H]1C(F)(F)F)C2=O)=O)=O MCOPHZCJGZMURT-SZNDQCEHSA-N 0.000 description 1
- WWWWHTDIVDUORX-QWHCGFSZSA-N NC(c(cc1)ccc1NC([C@@H](C[C@H]1OCCCC1)Br)=O)=O Chemical compound NC(c(cc1)ccc1NC([C@@H](C[C@H]1OCCCC1)Br)=O)=O WWWWHTDIVDUORX-QWHCGFSZSA-N 0.000 description 1
- JQBHAFKUYRFTKC-UHFFFAOYSA-N O=C1C(Cc(ccc(Cl)c2)c2Br)CC1 Chemical compound O=C1C(Cc(ccc(Cl)c2)c2Br)CC1 JQBHAFKUYRFTKC-UHFFFAOYSA-N 0.000 description 1
- KZVFUYHFHBBPPD-UHFFFAOYSA-N O=C1N(C=C(C=C2)Br)C2=NN1 Chemical compound O=C1N(C=C(C=C2)Br)C2=NN1 KZVFUYHFHBBPPD-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018122825 | 2018-12-21 | ||
| CNPCT/CN2018/122825 | 2018-12-21 | ||
| PCT/EP2019/085983 WO2020127504A1 (en) | 2018-12-21 | 2019-12-18 | Substituted oxopyridine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210106504A true KR20210106504A (ko) | 2021-08-30 |
Family
ID=69143542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217022510A KR20210106504A (ko) | 2018-12-21 | 2019-12-18 | 치환된 옥소피리딘 유도체 |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP3898633A1 (zh) |
| JP (1) | JP2022514303A (zh) |
| KR (1) | KR20210106504A (zh) |
| CN (1) | CN113474348A (zh) |
| AR (1) | AR117435A1 (zh) |
| AU (1) | AU2019407909B2 (zh) |
| BR (1) | BR112021009435A2 (zh) |
| CA (1) | CA3124220A1 (zh) |
| CL (1) | CL2021001613A1 (zh) |
| CO (1) | CO2021007908A2 (zh) |
| CR (1) | CR20210342A (zh) |
| DO (1) | DOP2021000128A (zh) |
| EA (1) | EA202191764A1 (zh) |
| EC (1) | ECSP21043895A (zh) |
| IL (1) | IL283990A (zh) |
| JO (1) | JOP20210161A1 (zh) |
| MA (1) | MA54521A (zh) |
| MX (1) | MX2021007508A (zh) |
| PE (1) | PE20211790A1 (zh) |
| SG (1) | SG11202104384PA (zh) |
| TW (1) | TW202039510A (zh) |
| WO (1) | WO2020127504A1 (zh) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111770917B (zh) * | 2018-03-15 | 2023-09-26 | 拜耳股份公司 | 两种化合物的制备方法 |
| CN114105881B (zh) | 2020-08-31 | 2024-01-26 | 沈阳海诺威医药科技有限公司 | 血小板聚集抑制剂及其制备方法和用途 |
| MX2023010629A (es) | 2021-03-09 | 2023-09-19 | Bayer Ag | Formas de dosificacion farmaceuticas que comprenden (4s)-24-cloro-4-etil-7?-fluoro-35-metoxi-3?,5-dioxo-14-(trifluoro metil)-3?h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola-2(1,2),7(1) -dibencenaheptafano-74-carboxamida. |
| BR112023016298A2 (pt) | 2021-03-09 | 2023-10-03 | Bayer Ag | Formas cristalinas de (4s)-24-cloro-4-etil-73-fluoro-35-metóxi-32,5-dioxo-14-(trifluoro-metil)-32h-6-aza-3(4,1)-piridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzena-heptafano-74-carboxamida |
| WO2022189280A1 (en) | 2021-03-09 | 2022-09-15 | Bayer Aktiengesellschaft | Solvates of (4s)-24-chloro-4-ethyl-73-fluoro-35-methoxy-32,5-dioxo-14-(trifluoro-methyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide |
| CN114560754A (zh) * | 2022-02-25 | 2022-05-31 | 滁州学院 | 一种烷基醇的制备方法 |
| CN116874469B (zh) * | 2023-09-06 | 2023-11-10 | 成都施贝康生物医药科技有限公司 | 一种氧代吡啶类化合物、中间体及其制备方法和用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| DE102006032824A1 (de) * | 2006-07-14 | 2008-01-17 | Bayer Healthcare Ag | Substituierte Indazole |
| EP2091947A2 (en) | 2006-12-20 | 2009-08-26 | Takeda San Diego, Inc. | Glucokinase activators |
| WO2014160592A2 (en) | 2013-03-27 | 2014-10-02 | Merck Sharp & Dohme Corp. | FACTOR XIa INHIBITORS |
| TWI633089B (zh) * | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | 經取代的酮基吡啶衍生物 |
| EP3024822B1 (de) | 2013-07-23 | 2017-05-03 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate und ihre verwendung als faktor xia und plasmakallikrein inhibitoren |
| JP6368367B2 (ja) | 2013-10-30 | 2018-08-01 | バイエル ファーマ アクチエンゲゼルシャフト | 置換オキソピリジン誘導体 |
| ES2722423T3 (es) * | 2014-09-24 | 2019-08-12 | Bayer Pharma AG | Derivados de oxopiridina sustituidos |
| ES2712886T3 (es) * | 2014-09-24 | 2019-05-16 | Bayer Pharma AG | Derivados de piridobenzazepina y piridobenzazocina que inhiben el factor XIa |
| ES2713624T3 (es) | 2014-09-24 | 2019-05-23 | Bayer Pharma AG | Derivados de oxopiridina sustituidos |
| EP3197872B1 (de) | 2014-09-24 | 2019-01-30 | Bayer Pharma Aktiengesellschaft | (2h)-2-oxopyridine als faktor xia-inhibitoren zur behandlung von thrombotischen erkrankungen |
| ES2694189T3 (es) | 2014-09-24 | 2018-12-18 | Bayer Pharma Aktiengesellschaft | Derivados de oxopiridina sustituidos |
| EP3197880B1 (de) | 2014-09-24 | 2018-10-24 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate mit anti-inflammatorischer und anti-thrombotischer wirkung |
| CN107428689A (zh) * | 2015-03-19 | 2017-12-01 | 拜耳制药股份公司 | 作为治疗血栓形成的因子xia抑制剂的氧代吡啶衍生物 |
| JO3703B1 (ar) | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | مشتقات أوكسوبيريدين مستبدلة |
| WO2017037051A1 (de) | 2015-09-04 | 2017-03-09 | Bayer Pharma Aktiengesellschaft | Substituierte oxopyridin-derivate |
-
2019
- 2019-12-18 WO PCT/EP2019/085983 patent/WO2020127504A1/en unknown
- 2019-12-18 CA CA3124220A patent/CA3124220A1/en active Pending
- 2019-12-18 PE PE2021000903A patent/PE20211790A1/es unknown
- 2019-12-18 JO JOP/2021/0161A patent/JOP20210161A1/ar unknown
- 2019-12-18 MX MX2021007508A patent/MX2021007508A/es unknown
- 2019-12-18 AU AU2019407909A patent/AU2019407909B2/en not_active Ceased
- 2019-12-18 SG SG11202104384PA patent/SG11202104384PA/en unknown
- 2019-12-18 AR ARP190103745A patent/AR117435A1/es unknown
- 2019-12-18 MA MA054521A patent/MA54521A/fr unknown
- 2019-12-18 JP JP2021535063A patent/JP2022514303A/ja active Pending
- 2019-12-18 EA EA202191764A patent/EA202191764A1/ru unknown
- 2019-12-18 CR CR20210342A patent/CR20210342A/es unknown
- 2019-12-18 KR KR1020217022510A patent/KR20210106504A/ko active Search and Examination
- 2019-12-18 CN CN201980091518.1A patent/CN113474348A/zh active Pending
- 2019-12-18 EP EP19832641.5A patent/EP3898633A1/en active Pending
- 2019-12-18 TW TW108146372A patent/TW202039510A/zh unknown
- 2019-12-18 BR BR112021009435-0A patent/BR112021009435A2/pt not_active Application Discontinuation
-
2021
- 2021-06-14 IL IL283990A patent/IL283990A/en unknown
- 2021-06-16 EC ECSENADI202143895A patent/ECSP21043895A/es unknown
- 2021-06-16 CO CONC2021/0007908A patent/CO2021007908A2/es unknown
- 2021-06-17 CL CL2021001613A patent/CL2021001613A1/es unknown
- 2021-06-18 DO DO2021000128A patent/DOP2021000128A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019407909B2 (en) | 2023-05-25 |
| CO2021007908A2 (es) | 2021-07-19 |
| IL283990A (en) | 2021-07-29 |
| DOP2021000128A (es) | 2021-09-30 |
| TW202039510A (zh) | 2020-11-01 |
| EA202191764A1 (ru) | 2021-10-22 |
| ECSP21043895A (es) | 2021-07-30 |
| CR20210342A (es) | 2021-08-09 |
| PE20211790A1 (es) | 2021-09-09 |
| JOP20210161A1 (ar) | 2023-01-30 |
| CA3124220A1 (en) | 2020-06-25 |
| MA54521A (fr) | 2022-03-30 |
| AU2019407909A1 (en) | 2021-05-27 |
| SG11202104384PA (en) | 2021-05-28 |
| BR112021009435A2 (pt) | 2021-08-17 |
| CL2021001613A1 (es) | 2021-12-03 |
| JP2022514303A (ja) | 2022-02-10 |
| AR117435A1 (es) | 2021-08-04 |
| WO2020127504A1 (en) | 2020-06-25 |
| EP3898633A1 (en) | 2021-10-27 |
| CN113474348A (zh) | 2021-10-01 |
| MX2021007508A (es) | 2021-08-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019407909B2 (en) | Substituted oxopyridine derivatives | |
| JP6368367B2 (ja) | 置換オキソピリジン誘導体 | |
| CN108026072B (zh) | 取代的氧代吡啶衍生物 | |
| CN106687458B (zh) | 取代的氧代吡啶衍生物 | |
| US10414731B2 (en) | Substituted oxopyridine derivatives | |
| US20180250280A1 (en) | Substituted oxopyridine derivatives | |
| CA3123324A1 (en) | Substituted oxopyridine derivatives for the treatment and/or prophylaxis of thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications | |
| JP2018502137A (ja) | 第ＸＩａ因子阻害剤 | |
| CZ20033325A3 (cs) | Deriváty pyrrolidinu jako inhibitory faktoru Xa | |
| TW201808908A (zh) | 因子XIa抑制劑 | |
| CA3124296A1 (en) | Substituted oxopyridine derivatives | |
| JP2016520113A (ja) | 血栓塞栓疾患の治療のためのトロンビン阻害薬としてのトリアゾロピリジン類 | |
| EA044932B1 (ru) | Замещенные оксопиридиновые производные | |
| TW202320754A (zh) | 經取代的ｓ－丙胺酸酯衍生物 | |
| CN116887831A (zh) | 因子XIa抑制剂 | |
| JP2016520111A (ja) | 置換ベンゾキサゾール | |
| JP2022183434A (ja) | テトラヒドロイミダゾピリジンカルボン酸化合物 | |
| JP2008512365A (ja) | 第Ｘａ因子阻害物質として使用する、Ｎ−（１−（２，３−ジヒドロ−１Ｈ−インデン−５イル）−２−オキソ−３−ピロリジニル）−スルホンアミド誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination |